Lin Wu

机构：Central South University, Hunan Cancer Hospital · ORCID：0000-0001-7078-7767

发表论文 459 篇 · 总被引 18214 次 · h-index 61

代表论文

• Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer (2025 · New England Journal of Medicine · 被引 52)
• Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T. (2025 · Journal of Clinical Oncology · 被引 22)
• First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial (2025 · Nature Medicine · 被引 20)
• Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials (2025 · 癌症：英文版 · 被引 12)
• TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study (2025 · Cancer Cell · 被引 10)
• Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions (2025 · Cancers · 被引 9)